Date: Apr 23, 2015 Author: Deanna Pogorelc Source: MedCityNews (
click here to go to the source)
Boston Children's Hospital stirred up some buzz in June when it said its researchers had made a breakthrough that could change the face of diabetes treatment.
Insulin startup Thermalin Diabetes has earned itself an esteemed new partner in its quest to develop formulations of insulin that will give people with diabetes tighter control over their blood sugar levels.
Cleveland-based Thermalin said today that JDRF will provide it with up to $1 million for specific milestones related to identifying a clinical candidate insulin analog with a shorter tail of action.
The company's innovation is based on engineering advances made in the lab of Michael Weiss, the chairman of biochemistry at Case Western Reserve Medical School. The JDRF grant will allow Weiss and his team to build on their study of how insulin binds with proteins on cells. In January of last year, the team had a paper published in Nature in which they described in detail the 3D structure of insulin and receptors that it binds to.
Advertisement
Thermalin's goal with this project is to manipulate how insulin binds with receptors so that it kicks in quicker and lasts for a shorter period of time. That could potentially curb the need for people with diabetes to snack to avoid a blood sugar dip a few hours after a meal, said CEO Rick Berenson.
Current rapid-acting insulin has a tail of three to four hours after it's injected, Berenson said. "The goal is to have an insulin that is done acting in the two-hour time frame so that it matches more precisely the glucose spike from carbohydrates with a meal."
When insulin lasts longer than it takes the body to convert the food that's been eaten into glucose, blood sugar levels get low. "That makes people not feel so good, so they'll snack to get their blood sugar back up," Berenson explained. "That's thought to be a major reason for weight gain."
A shorter duration of action would be good for daily injection but also for future versions of the artificial pancreas system, he said. First-generation artificial pancreas devices will proactively respond to readings from blood glucose meters. The challenge is that algorithms in pumps can't initially determine whether blood sugar levels are going up a lot from a meal, or a little from a snack.
"Insulin lasts three to four hours, so if it guesses wrong, the effects of that mistake will last three to four hours," he said. By creating a shorter tail of action, Thermalin hopes to enable algorithms to maintain tighter control over blood sugar levels.
JDRF, a key source of funding and research toward an artificial pancreas, will contribute funding and an advisory board for the project. Thermalin has committed matching funds..
Meanwhile, Thermalin is also developing other insulin analogs aimed at making insulin injections faster-acting, longer-lasting or more stable based on the needs of different kinds of diabetics. Its lead candidate is an ultra-concentrated, rapid-acting insulin. Berenson said that program should begin IND-enabling studies this summer, with an IND to follow early next year.
The company has been funded by $7.8 million in NIH grants and has raised $9.4 million in equity.
39
Hear the latest industry news first
Get our daily newsletter or follow us.
Share on facebook Share on twitter Share on linkedin Share on rss
Please enter your email below:
Deanna Pogorelc
By Deanna Pogorelc MedCity News
Deanna Pogorelc is a Cleveland-based reporter who writes obsessively about life science startups across the country, looking to technology transfer offices, startup incubators and investment funds to see what's next in healthcare. She has a bachelor's degree in journalism from Ball State University and previously covered business and education for a northeast Indiana newspaper.
More posts by Author
3 comments
Livefyre
Sign in or Post as Guest
2 people listening
trunks_cscs
Newest | Oldest | Top Comments
trunks_cscs
trunks_cscs Jun 8, 2014
A major problem is not everybody has subcutaneous fat stores that will allow for rapid absorption. Scar tissue is a problem that I see. I have scar tissue and fibrous masses because, if you race bikes, you crash bikes. What about use in infusion pumps? Insulin pumps are used by a larger population than injection so I would see that as a main concern. On another note, I have a Master's in exercise physiology specializing in the effect if exercise intensity on glucoregulation in diabetes so I'd like to see the application of a rapid acting insulin on reducing HGP which is the cause of post-exercise hyperglycemia.
FlagShare
LikeReply
richardberenson
richardberensonOct 28, 2014
@trunks_cscs The new insulin is designed to work in pumps!
FlagShare
LikeReply
PTurner
PTurnerApr 23, 2014
I'm sure the quote from Berenson was that people don't "feel so good" as opposed to "feed so good".
FlagShare
LikeReply
GOT NEWS? SEND US A TIP
Latest Stories
Jon Stewart puts the spotlight on gun-nosy doctors 9:16 am
Patience on King v. Burwell, AbbVie's big cancer buy and here comes L.A. superbug 2.0 (Morning Read) 6:55 am
Aura Biosciences pulls in $21M for tumor-targeted rare eye cancer therapy 6:54 am
One week in Chicago with Matter, MedCity News and Forbes 5:00 am
From the MedCity Team
Stephanie Baum
Mayo Clinic and Gentag ink IP collaboration to commercialize biosensors for diabetes, obesity
Stephanie Baum | 8:27 pm, March 4
Meghana Keshavan
Venture perspectives on the venture climate: #CEDLSC15
Meghana Keshavan | 7:02 pm, March 4
Dan Verel
First Databank, Polyglot team up on medication adherence
Dan Verel | 9:28 pm, March 4
Chris Seper
One week in Chicago with Matter, MedCity News and Forbes
Chris Seper | 5:00 am, March 5
Nicole Oran
Jon Stewart puts the spotlight on gun-nosy doctors
Nicole Oran | 9:16 am, March 5
Thought Leaders
Dr. John D. Halamka
Where does the ONC go in a post-Meaningful Use world?
Dr. John D. Halamka | 11:15 am, March 1
Kathryn Stecco, M.D.
5 basic principles to help women succeed in the medical device industry
Kathryn Stecco, M.D. | 11:11 am, March 1
Lisa Suennen
My patient experience: at times comforted and other moments abandoned
Lisa Suennen | 9:09 pm, February 15
